Cueva-Parra Á, Neach-De la Vega D, Ortiz-Solís W, Fernández-Domenech J, Lara-Aguilera S, Chi-Pool S, Muñoz-Benavides G, Bustillos-García G, Márquez-Murillo M, Gómez-Flores J, Levinstein-Jacinto M, Mendoza-G C, Nava-Townsend S

Language: Spanish
References: 12
Page: 222-228
PDF size: 269.54 Kb.

Text Extraction

No abstract.

REFERENCES

1. Clinical management of severe acute respiratory infection when COVID-19 disease is suspected [Internet]. World Health Organization; 2020 [consultado el 27 de marzo de 2020]. Disponible en: https://www. who.int/publications-detail/clinical-management-of-severe-acute-respira- tory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected

2. Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTC prolonging and tor- sadogenic potential of possible pharmacotherapies for COVID-19. Mayo Clin Proc. 2020 Apr 7. doi: 10.1016/j.mayocp.2020.03.024. [Epub ahead of print]

3. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [published online ahead of print, 2020 Mar 20]. Int J Antimicrob Agents. 2020; 105949.

4. Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J. 2007; 153 (6): 891-899.

5. Tisdale JE, Wroblewski HA, Overholser BR, Kingery JR, Trujillo TN, Kovacs RJ. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US. Drug Saf. 2012; 35 (6): 459-470.

6. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart. 1920; 7: 35-70.

7. Márquez MF. El síndrome de QT largo: una breve revisión del diagnóstico electrocardiográfico incluyendo la prueba de Viskin. Arch Cardiol Mex. 2012; 82 (3): 243-247.

8. Asensio E, Acunzo R, Uribe W, Saad EB, Sáenz L. Recomendaciones para la medición del intervalo QT durante el uso de medicamentos para el tratamiento de infección por COVID-19. Actualizables de acuerdo con la disponibilidad de nueva evidencia [Internet]. Sociedad Latinoamericana del Ritmo Cardiaco (LAHRS), Colegio Colombiano de Electrofisiología, Sociedad Argentina de Electrofisiología Cardiaca (SADEC), Sociedad Brasileña de Arritmias Cardiacas (SOBRAC), Sociedad Mexicana de Electrofisiología Cardiaca (SOMEEC). Disponible en: https://www.sociedadsadec.org.ar/wp-content/uploads/2020/04/RECOMENDACIONES-PARA-LA-MEDICION-DEL-INTERVALO-QT-DURANTE-EL-USO-DE-MEDICAMENTOS-PARA-EL-TRATAMIENTO-DE-INFECCION-POR-COVID.pdf

9. Choi Y, Lim HS, Chung D, Choi JG, Yoon D. Risk Evaluation of azithromycin-induced QT prolongation in real-world practice. Biomed Res Int. 2018; 2018: 1574806.

10. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020 Mar 18. doi: 10.1016/j.jacc.2020.03.031. [Epub ahead of print]

11. Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013; 6 (4): 479-487.

12. Tisdale JE, Jaynes HA, Kingery JR, Overholser BR, Mourad NA, Trujillo TN et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2014; 7 (3): 381-390.